Predictors of heartburn resolution and erosive esophagitis in patients with GERD

References

• Dean BB, Gano Jr AD, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004;2:656-64
   PubMed Web of Science ®Google Scholar
• Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965-73
   PubMed Web of Science ®Google Scholar
• Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998;10:119-224
   PubMed Web of Science ®Google Scholar
• Armstrong D, Pare P, Pericak D, et al. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 2001;96:2849-57
   PubMed Web of Science ®Google Scholar
• Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management—The Genval Workshop Report. Gut 1999;44(Suppl 2):S1-16
   PubMed Web of Science ®Google Scholar
• Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990;335:205-8
   PubMed Web of Science ®Google Scholar
• Martinez SD, Malagon IB, Garewal HS, et al. Non-erosive reflux disease (NERD)—acid reflux and symptom patterns. Aliment Pharmacol Ther 2003;17:537-45
   PubMed Web of Science ®Google Scholar
• Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 2005;128:771-8
   PubMed Web of Science ®Google Scholar
• Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002;51:885-92
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Lind T, Willich S, et al. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut 2005;54:746-51
   PubMed Web of Science ®Google Scholar
• Talley NJ, Armstrong D, Junghard O, et al. Predictors of treatment response in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2006;24:371-6
   PubMed Web of Science ®Google Scholar
• Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-9
   PubMed Web of Science ®Google Scholar
• Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998;33:1023-9
   PubMed Web of Science ®Google Scholar
• Labenz J, Jaspersen D, Kulig M, et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol 2004;99:1652-6
   PubMed Web of Science ®Google Scholar
• World Medical Association. Declaration of Helsinki V: ethical principles for medical research involving human subjects. In: 52nd World Medical Assembly, October 2000; Edinburgh, Scotland, 2000
   Google Scholar
• European Agency for the Evaluation of Medicinal Products. International Conference on Harmonisation – World Health Organization, Guideline for Good Practice. ICH Topic E6: Geneva: WHO 2002. Available at: http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf [Last accessed 2 December 2008]
   Google Scholar
• Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-80
   PubMed Web of Science ®Google Scholar
• Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656-65
   PubMed Web of Science ®Google Scholar
• Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575-83
   PubMed Web of Science ®Google Scholar
• Katz PO, Castell DO, Levine D. Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 2003;18:875-82
   PubMed Web of Science ®Google Scholar
• Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol 2004;2:665-8
   PubMed Web of Science ®Google Scholar
• Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996;111:1192-9
   PubMed Web of Science ®Google Scholar
• Cicala M, Emerenziani S, Caviglia R, et al. Intra-oesophageal distribution and perception of acid reflux in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003;18:605-13
   PubMed Web of Science ®Google Scholar
• Gardner JD, Gallo-Torres H, Sloan S, et al. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis. Aliment Pharmacol Ther 2003;18:891-905
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Sonnenberg A. Associations between different forms of gastro-oesophageal reflux disease. Gut 1997;41:594-9
   PubMed Web of Science ®Google Scholar
• Aro P, Ronkainen J, Talley NJ, et al. Body mass index and chronic unexplained gastrointestinal symptoms: an adult endoscopic population based study. Gut 2005;54:1377-83
   PubMed Web of Science ®Google Scholar
• Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005;143:199-211
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Johanson JF. Risk factors for the severity of erosive esophagitis in Helicobacter pylori-negative patients with gastroesophageal reflux disease. Scand J Gastroenterol 2002;37:899-904
   PubMed Web of Science ®Google Scholar
• Shaw MJ, Talley NJ, Beebe TJ, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001;96:52-7
   PubMed Web of Science ®Google Scholar
• Eisen G. The epidemiology of gastroesophageal reflux disease: what we know and what we need to know. Am J Gastroenterol 2001;96(Suppl):S16-8
   PubMedGoogle Scholar